United Therapeutics Corp Live Stock Price Today, Share Analysis and Chart

Name: United Therapeutics Corp: Is Infosys Ltd. worth buying?
Item: United Therapeutics Corp
Rating: 2.795486125
Author: Trendlyne DVM scores

Mid-range Performer

about

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on...

464.93 -7.06 (-1.50%)

74.14% Gain from 52W Low

397.7K

XNAS Volume

XNAS 16 Jan, 2026 4:30 PM (EST)

High Financial Strength

61.1 / 100

Mid Valuation

44.7 / 100

Technically Neutral

56.8 / 100

Mid-range Performer These stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investors View Similar Embed DVM

531

1Yr Price target upside is 14%

12 analysts

United Therapeutics Corp Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

United Therapeutics Corp Live Stock Price Today, Share Analysis and Chart

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on...

74.14% Gain from 52W Low

SWOT Analysis

United Therapeutics Corp Live Price Chart